Few states in India have started plasma therapy trials and HCQ is in administration to fight against COVID-19.

Statements by officials show that trials of blood plasma therapy for COVID-19 in few states of India had been started.

Statements by officials show that trials of blood plasma therapy for COVID-19 in few states of India had been started.In an exclusive interview to ANI Karnataka Health Minister Dr Sudhakar said that the Karnataka government on 25 April 2020 commenced convalescent plasma therapy clinical trials for severe coronavirus patients in the state. The official transfusion of plasma from a person who has recovered from COVID-19 had started.

Dr Asha Kishore Director, Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) informed that Indian council for medical research (ICMR) approved SCTIMST for carrying out the novel blood plasma therapy for COVID-19. Further stated that the institute is seeking permission from Drug Controller General of India (DCGI) for relaxation of the norms for blood donation.

According to The Hindu and India Today articles, since the Indian council for medical research (ICMR) approved the usage of hydroxychloroquine (HCQ) tablets to treat COVID-19, it is taken as a preventive measure by front-line healthcare workers and patients. A senior official from Brihanmumbai Municipal Corporation (BMC) informed that there are adequate tablets and government made sufficient provision to ensure the availability of the tablet.

A private hospital in Indore, Madhya Pradesh on 27 April 2020 had also started plasma therapy trials on three coronavirus patients who were in serious condition.

The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.